Today, dozens of companies produce CBD in an array of forms. CBD can be inhaled through vape pens, applied in topical salves, ingested in edibles, or swallowed in oil-based tinctures. Oil has become the dominant CBD delivery method for kids with epilepsy, since it is easy to administer and ingest, and there is no shortage of it available for sale online. There are dozens of companies boasting names like Healthy Hemp Oil, Dose of Nature, and Natural Organic Solutions, each of them selling CBD products at prices ranging from trivial to dizzyingly steep. You don’t have to look hard to find them. If you have a PayPal account and $100 to spare, you could have a vial of hemp oil delivered to your doorstep.
An industrial hemp license issued by the state provides authorization for the production of industrial hemp at a particular growing area by a particular individual or entity. Licenses will expire on the last day of December of the year that they are issued. Renewals do not require new fingerprinting unless the department requests it or if the corporate officers have changed.
Some of the research focuses that were explored in 2018 were: comparison of various agronomic factors on industrial hemp (planting dates, tillage regimens, range of soil fertility, etc.); hemp variety comparison for suitability to PA growing conditions; study of the effectiveness of potential herbicide products; comparison of hemp’s capability for weed suppression to other crops; surveying hemp crops for presence of arthropod and disease pests; evaluation of hemp’s performance for phytoremediation and land reclamation; study of hemp seed oil processing and marketability; development of industrial hemp products (using grain, stalks and flowers); genetic selection for desired hemp variety characteristics; and evaluations of hemp as an animal feed ingredient (cattle).
In September 2018, following its approval by the FDA for rare types of childhood epilepsy, Epidiolex was rescheduled (by the Drug Enforcement Administration) as a Schedule V drug to allow for its prescription use. This change applies only to FDA-approved products containing no more than 0.1 percent THC. This allows GW Pharmaceuticals to sell Epidiolex, but it does not apply broadly and all other CBD-containing products remain Schedule I drugs. Epidiolex still requires rescheduling in some states before it can be prescribed in those states.
The US Office of National Drug control Policy issued a statement on industrial hemp in 1997 (www.whitehousedrugpolicy.gov/policy/hemp%5Fold.html) which included the following: “Our primary concern about the legalization of the cultivation of industrial hemp (Cannabis sativa) is the message it would send to the public at large, especially to our youth at a time when adolescent drug use is rising rapidly... The second major concern is that legalizing hemp production may mean the de facto legalization of marijuana cultivation. Industrial hemp and marijuana are the product of the same plant, Cannabis sativa... Supporters of the hemp legalization effort claim hemp cultivation could be profitable for US farmers. However, according to the USDA and the US Department of Commerce, the profitability of industrial hemp is highly uncertain and probably unlikely. Hemp is a novelty product with limited sustainable development value even in a novelty market... For every proposed use of industrial hemp, there already exists an available product, or raw material, which is cheaper to manufacture and provides better market results.... Countries with low labor costs such as the Philippines and China have a competitive advantage over any US hemp producer.”
Separate levels of evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and scientific strength of the treatment outcomes (i.e., endpoints) measured. The resulting two scores are then combined to produce an overall score. An overall level of evidence score cannot be assigned to cannabinoids because there has been insufficient clinical research. For an explanation of possible scores and additional information about levels of evidence analysis of CAM treatments for people with cancer, refer to Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies.
Epidiolex is the first FDA-approved treatment in the U.S. that contains a purified drug substance derived from marijuana -- CBD -- and the first treatment for Dravet syndrome. In September 2018 the FDA rescheduled cannabidiol from a C-I controlled substance to a C-V controlled substance, meaning it has a proven medical use but a low risk of abuse. This change allows Epidiolex to be marketed in the U.S.
A systematic review assessing 19 studies that evaluated premalignant or malignant lung lesions in persons 18 years or older who inhaled Cannabis concluded that observational studies failed to demonstrate statistically significant associations between Cannabis inhalation and lung cancer after adjusting for tobacco use. In the review of the published meta-analyses, the National Academies of Sciences, Engineering, and Medicine (NASEM) report concluded that there was moderate evidence of no statistical association between Cannabis smoking and the incidence of lung cancer.
From 1982 to 2002 the EU provided the equivalent of about 50 million dollars to develop new flax and hemp harvesting and fiber processing technologies (Karus et al. 2000). Because of the similarities of flax and hemp, the technologies developed for one usually are adaptable to the other. In addition, various European nations and private firms contributed to the development of hemp technologies. Accordingly, Europe is far more advanced in hemp development with respect to all fiber-based applications than other parts of the world. The EU currently dedicates about 30,000 ha to hemp production. France is the leading country in hemp cultivation in the EU, and 95% of the non-seed production is used for “specialty pulp” as described below. Harvesting and processing machinery for fiber hemp is highly advanced in Europe, and some has been imported into Canada. However, there is insufficient fiber processing capacity to handle hemp produced in Canada.
For kids with severe forms of epilepsy, changes in medication levels can be extremely dangerous. “If their levels go low, they’re at increased risk of seizures, which could lead to an emergency room visit or an ICU stay,” Knupp said. “On the other hand, if their levels go high, their side effects can increase dramatically.” Side effects from epilepsy medications can range anywhere from drowsiness to vomiting to heart arrhythmia, Knupp noted. “For some people that could mean a minor inconvenience, but for some patients it could be life-threatening.”
The term kief refers to the sticky, bulbous crystalline formations on the tip of a gland called a “trichome.” Trichomes are external resin glands packed with the chemicals that give marijuana its flavors and smells, called “terpenes.” They also contain high concentrations of cannabinoids. These chemicals which interact with our body to produce marijuana’s signature effects.
The Department has policies and procedures in place for the commonwealth's hemp research program, which can be found in the 2019 Pilot Program Parameters. Researchers from institutions of higher education or growers who would like to be considered for participation in the 2019 program must submit a 2019 PDA Industrial Hemp Research Pilot Program Permit Application prior to the application deadline of December 17, 2018. Researchers who participated in the 2018 Pilot Program may submit a Permit Renewal form by December 17, 2018 to continue their projects in the 2019 growing season.
Elias Anderson, one of the owners of Going Green, said representatives from HempMedsPx approached him after Krenzler published the lab’s findings on his blog. “They were like, ‘What are we gonna do about it?’” Anderson recalled, “And I was like, ‘Nothing. We have standards, and I stand behind my test results.’” Still, the company’s representatives were insistent and advised Anderson to have Kenzler take down the lab’s findings. In an email to the New Republic, Hard, the Medical Marijuana, Inc. spokesman, contended that the sample of hemp oil that Going Green Labs tested had been “tampered with” by a competitor after Krenzler obtained it. “HempMedsPX, if anything, told the lab they cannot publish results from products [for which] they had no chain of custody tracked,” Hard said, “and if they did—that could prove to be very bad for the lab.” He also characterized Krenzler and Anderson as “haters” of Medical Marijuana, Inc., and suggested that much of the criticism of the company and its products comes from commercial competitors.
“Hemp is of high nutritional quality because it contains high amounts of unsaturated fatty acids… Linoleic acid and alpha-linolenic acid are the only two fatty acids that must be ingested and are considered essential to human health … In contrast to shorter-chain and more saturated fatty acids, these essential fatty acids do not serve as energy sources, but as raw materials for cell structure and as precursors for biosynthesis for many of the body’s regulatory biochemicals…”